Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus lenvatinib or sorafenib versus lenvatinib or sorafenib alone in previously treated unresectable hepatocellular carcinoma
2020-005231-78Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, lenvatinib and sorafenib in hepatocellular carcinoma (HCC) (4 arms), sponsored by Roche. Primary endpoint: Overall survival. Started Jan 2021; status: active.
02
Drugs
atezolizumablenvatinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-005231-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005231-78.